Work

Second-Generation ALK Inhibitors: Filling the Non “MET” Gap

Year: 2014

Type: article

Abstract: Summary: Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provide new options for the management of ALK-positive NSCLC. Cancer Discov; 4(6); 634–6. ©2014 AACR. See related article by Friboulet et al., p. 662

Source: Cancer Discovery

DOI: 10.1158/2159-8290.cd-14-0410

Authors: Suresh S. Ramalingam, Fadlo R. Khuri

Institutions: Emory University, Winship Cancer Institute

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute